AstraZeneca and Rigel strike asthma deal worth up to $100M
The deal hinges on Rigel's candidate known as R256, an inhalable JAK inhibitor under evaluation for treating tough cases of asthma.
AstraZeneca And Rigel Sign Worldwide License Agreement For A …
AstraZeneca, Rigel to Develop Asthma Treatment
Rigel, AstraZeneca strike potential $100M asthma drug deal
View full post on asthma – Google News